Interim 2023/2024 Season Influenza Vaccine Effectiveness in Primary and Secondary Care in the United Kingdom

• DOI: 10.1111/irv.13284
• Publication Date: 2024-05-22T05:11:24Z
• Authors: Heather Whitaker; Beth Findlay; Jana Zitha; Rosalind Goudie; Katie Hassell; Josie Evans; Panoraia Kalapoth...; Utkarsh Agrawal; Beatrix Kele; Mark Hamilton; Catherine Moore; Rachel Byford; Julia Stowe; Chris Robertson; Anastasia Couzens; Gavin Jamie; Katja Hoschler; Kathleen Pheasant; Elizabeth Button; Catherine Quinot; Tim Jones; Sneha Anand; Conall Watson; Nick Andrews; Simon de Lusignan; Maria Zambon; Christopher Williams; Simon Cottrell; Kimberly Marsh; Jim McMenamin; Jamie Lopez Bernal
• Keywords: Adult; Male; Adolescent; Public health. Hygiene. Preventive Medicine; Short Communications; 610; Vaccine Efficacy; Secondary Care; Young Adult; 03 medical and health sciences; Influenza A Virus, H1N1 Subtype; 0302 clinical medicine; Influenza, Human; Humans; Child; Aged; Primary Health Care; Influenza A Virus, H3N2 Subtype; Vaccination; Middle Aged; United Kingdom; Influenza Vaccines; Child, Preschool; Female; Seasons

ABSTRACTBackgroundWe report 2023/2024 season interim influenza vaccine effectiveness for three studies, namely, primary care in Great Britain, hospital settings in Scotland and hospital settings in England.MethodsA test negative design was used to estimate vaccine effectiveness.ResultsEstimated vaccine effectiveness against all influenzas ranged from 63% (95% confidence interval 46 to 75%) to 65% (41 to 79%) among children aged 2–17, from 36% (20 to 49%) to 55% (43 to 65%) among adults 18–64 and from 40% (29 to 50%) to 55% (32 to 70%) among adults aged 65 and over.ConclusionsDuring a period of co‐circulation of influenza A(H1N1)pdm09 and A(H3N2) in the United Kingdom, evidence for effectiveness of the influenza vaccine in both children and adults was found.